140 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
13 Aug 24
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
9:05am
,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking
8-K
EX-99.1
PULM
Pulmatrix, Inc.
29 May 24
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
8:45am
,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets
8-K
EX-99.1
PULM
Pulmatrix, Inc.
15 May 24
Regulation FD Disclosure
9:00am
,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify
8-K
EX-99.1
rea49ssh2g2zfjnqcu
10 May 24
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
dppry1 kxsh
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
9gnoxq2j2
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
8-K
EX-99.1
6j72s jh89xzvlh7afi3
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
g3i1qam
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
aew5q80h5y2lmha4r71
11 Jul 23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
9:05am
8-K
EX-99.1
wjeq2p4bfid qtlzw9
12 May 23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
9ni 7b6pmno6ut
30 Mar 23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
9:05am
8-K
EX-99.1
g2vavo1s9dmp9v
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am